Pharmaceuticals - Community Register

  

Community list of not active orphan medicinal products


WITHDRAWN  

Product information

Ramucirumab

EU orphan designation number: EU/3/12/1004
Active ingredient: Ramucirumab
Indication: Treatment of gastric cancer
Sponsor: Eli Lilly Nederland B.V.
Grootslag 1-5, NL-3991 RA Houten, Nederland
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Cyramza on 19/12/2014 with the number EU/1/14/957

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
06/07/2012 Orphan designation EMA/OD/030/12 (2012)4762 of 04/07/2012
22/12/2015 Removal of orphan designation from Community Register